Skip to Content
Merck
  • [Modern approach to the neuromuscular blocking agents use in pediatric patients].

[Modern approach to the neuromuscular blocking agents use in pediatric patients].

Anesteziologiia i reanimatologiia (2013-07-03)
E G Agavelyan, S M Stepanenko
ABSTRACT

Myorelaxants use decrease trend appeared since the end of 80 years of the 20th century. The trend is connected with use of the new narcotic analgesics (Remifentanil), intravenous (Propofol) and inhalation (Sevoflurane) anaesthetics. These drugs are manageable and predictable, they have not many side effects and can suppress laryngeal-pharyngeal reflex during the tracheal intubation. Furthermore there are other factors such as succinylcholines use when fast intubation is needed, the wrong myorelaxant and dosage choice. Residual curarization and side effects risk increases due to these factors. As a result the patient's activation is delayed. Nevertheless myorelaxants use refusal impairs the tracheal intubation conditions, increases the arterial hypotension and heart failure risk especially in newborns and children with severe pathology. If myorelaxants is not used, comfortable conditions of surgical manipulations impossible without big analgesics and anaesthetics doses use.

MATERIALS
Product Number
Brand
Product Description

Propofol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Sevoflurane, European Pharmacopoeia (EP) Reference Standard
Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Propofol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®